NCT06743308 Novel INPUT Screening Tool to Improve Illness Understanding in Patients With Metastatic or Incurable Lung Cancer
| NCT ID | NCT06743308 |
| Status | Recruiting |
| Phase | — |
| Sponsor | M.D. Anderson Cancer Center |
| Condition | Lung Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-12-16 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2024-12-16 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial compares the use of a new screening tool designed to evaluate patients' information needs, preferences, and illness understanding to the usual care to improve illness understanding in patients with lung cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or for which no curative treatment is currently available (incurable). Goal concordant care is a model of care that aligns a patient's medical care with their values, preferences, and goals. Often, patients may not fully understand their illness and prognosis, but this information is important so that they can make fully informed decisions regarding their care that are consistent with their values, preferences, and goals. Completing the Information Needs, Preferences, and Understanding Trial (INPUT) screening tool may allow for more frequent and regular discussions regarding disease status and treatment goals, ultimately resulting in improved patient illness understanding and goal concordant care for patients with metastatic or incurable lung cancer.
Eligibility Criteria
Inclusion Criteria: * Within 3 months of biopsy-confirmed diagnosis of stage IV lung cancer * Age 18 or over * English speaking * Attending a follow-up visit at the thoracic medical oncology clinic * Plans to receive or actively undergoing cancer-directed systemic treatment at MD Anderson Exclusion Criteria: • Diagnosis of cognitive impairment or dementia requiring a surrogate decision maker
Contact & Investigator
Kayley Ancy, MD
PRINCIPAL INVESTIGATOR
M.D. Anderson Cancer Center
Frequently Asked Questions
Who can join the NCT06743308 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06743308 currently recruiting?
Yes, NCT06743308 is actively recruiting participants. Contact the research team at kmclemings@mdanderson.org for enrollment information.
Where is the NCT06743308 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT06743308 clinical trial?
NCT06743308 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Kayley Ancy, MD at M.D. Anderson Cancer Center. The trial plans to enroll 100 participants.